Author:
Emlet D R,Schwartz R,Brown K A,Pollice A A,Smith C A,Shackney S E
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, Averbuch S, Baselga J (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274–1283
2. Arteaga C, Baselga J (2003) Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 9: 1579–1589
3. Arteaga C, Truica C (2004) Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Semin Oncol 31: 3–8
4. Arteaga CL, Baselga J (2004) Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 5: 525–531
5. Baselga J (2001) Clinical trials of Herceptin(trastuzumab). Eur J Cancer 37: S18–S24
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献